Germany's BfArM to lead HTA for digital health productsGerman drugs' regulator BfArM will be responsible for the approval and health technology assessment (HTA) of digital health products from January 2020, under the "better care by digitisation and innovation" (DVG) bill presented on Wednesday, FAZ (p16) and Handelsblatt (p6-7) reported on Thursday (APMHE 63657).
Merck KGaA develops robot to diagnose thyroid diseaseMerck KGaA has developed a robot able to check for thyroid disease, says Handelsblatt on Friday (p19).
End of homeopathy reimbursement in France finds echos in GermanyThe decision by France's health minister to end reimbursement of homeopathic products from 2021 has given new arguments to German globules opponents, weekly Wirtschaftswoche (p60-61) on Friday, FAZ (p15) and Die Welt (p20) on Thursday.
German doctors sceptical about female libido drug VyleesiGerman physicians are sceptical about the effect of Palatin Technologies/AMAG Pharmaceuticals' Vyleesi (bremelanotide), approved as a female sexual stimulant for premenopausal women last week by the U.S. Food and Drug Administration, FAZ reported on Sunday (p53) (APMHE 63440).
Pharma prices do not have to be revealed in U.S. TV ads - court rulingThe U.S. Ministry of Health cannot force pharma companies to publish their prices in television advertisements as the U.S. Congress has not authorised this action, a federal judge has ruled, FAZ reported on Wednesday (p19) (APMHE 63632).
Antibiotics weaken flu defencesAntibiotics can leave the lung vulnerable to flu viruses, leading to significantly worse infections and symptoms, according to a study in mice published in Cell reports, Die Welt on Wednesday (p20) reported.
M&A focus on gene therapiesDuring the first half of this year, pharma companies and biotechs have been focusing on gene therapies for mergers and acquisitions (M&A), according to a study by consulting firm KPMG, FAZ wrote on Monday (p20).
Reckitt Benckiser settles U.S. opioid litigation for $1.4 billionUK healthcare group Reckitt Benckiser will pay up to $1.4 billion to settle all U.S. federal over marketing strategies of opioid addiction treatment Suboxone (buprenorphine+naloxone) film by its former prescription pharmaceuticals business Indivior, FAZ reports on Friday (p20) (APMHE 63658).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.